CA-VERIMATRIX/TELESTREAM
29.8.2022 17:46:43 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, and Telestream, a global leader in video quality monitoring, test and measurement solutions, today announced that Surveyor ABR Active, Telestream iQ's ABR streaming QoE and QoS monitoring technology, is integrated within Verimatrix StreamkeeperSM Multi-DRM, available in the Verimatrix Secure Delivery Platform.
Through the integration, Telestream further builds on its innovative offerings for the digital video industry which include workflow automation, media processing, and quality monitoring solutions for the production and distribution of video. Telestream’s integration with Streamkeeper Multi-DRM allows users to capitalize on Verimatrix’ s cost-effective cloud-based solution while maintaining full visibility into video and audio content quality. Together, Verimatrix and Telestream accelerate time to market while maintaining service visibility for operators.
Verimatrix Streamkeeper Multi-DRM delivers studio endorsed best practices for content protection, with meticulous focus on ensuring superior video viewer experiences. As a suite of adaptive cybersecurity technologies that include and go beyond DRM, Streamkeeper allows video service providers to manage revenue risk in a world of continuously changing threats from video piracy and cybercriminals.
Telestream’s video quality monitoring solutions are trusted worldwide to provide video service assurance and operational visibility for valuable live and on-demand video services. As digital workflows move to the cloud, Telestream’s pedigree monitoring solutions, coupled with Verimatrix, means those planning to migrate their video workflows to the cloud will have equal or better operational visibility than ever before.
Telestream iQ provides full video and audio quality analysis both at the transcoding location and post CDN for live and on-demand services, allowing operators full visibility into content quality issues – even with full security encryption in place. Telestream iQ’s solutions ensure that audio and video quality errors such as compression errors, pixelization, black screen, still frame, and audio loudness are caught early, allowing rapid time-to-resolution and the ongoing protection of revenue and reputation.
“A longstanding alliance partner of Verimatrix, Telestream is proud to be one of its first partners to integrate with Streamkeeper Multi-DRM,” said Joel Daly, vice president of product management at Telestream. “Together we provide a solution that builds security, service assurance and operational visibility into cloud video workflows, de-risking the migration to cloud for global content and video service providers.”
“We’re extremely pleased to work with such highly-recognized industry visionaries such as Telestream as we continue to widen the number the number of integrated solutions available within Verimatrix Streamkeeper Multi-DRM,” said Sebastian Braun, senior director of product management at Verimatrix. “We’re pleased to continue our acceleration of additive value adoption through a global network of trusted partners.”
Verimatrix Streamkeeper is available in multiple tiers and includes features such as a real-time performance dashboard, on-call support integrations and alerts, individual device risk scoring and anti-piracy countermeasures.
Surveyor ABR Active provides essential insights that enable content owners and streaming service providers to manage critical issues relate to Quality of Service (QoS) and Quality of Experience (QoE) for live and on-demand services. It acts as the most critical viewer, measuring video flows for every bitrate variant and format.
For more information about Verimatrix Streamkeeper, visit: www.verimatrix.com/products/streamkeeper.
About Telestream
For nearly 25 years, Telestream® has been at the forefront of innovation in the digital video industry. The company develops products for media processing and workflow orchestration, live capture, streaming, production, video quality assurance, virtual events and video hosting, content management, and video and audio test solutions. Available on premises or in the cloud as well as in hybrid combinations, Telestream solutions make it possible to reliably get video content to any audience, regardless of how it is created, distributed or viewed. Telestream is privately held with corporate headquarters located in Nevada City, California and Westwood, Massachusetts.
For company and product information, visit www.Telestream.net.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
